Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8+ T lymphocytes by the endogenous tumor antigen1

Journal of Immunology

Volumn 167, Issue 12, 2001, Pages 6947-6956

  Schell, T D ^a   Tevethia, S S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; VIRUS T ANTIGEN;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GAMMA IRRADIATION; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; SPLEEN CELL; TRANSGENIC MOUSE; VIRUS TRANSFORMATION;

EID: 0035892986     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.12.6947     Document Type: Article

References (72)

1. Tumor antigens recognized by T lymphocytes
2. Progress in human tumour immunology and immunotherapy
3. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
4. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors
5. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
6. Transgenic animal models of human papillomavirus-dependent disease
7. Transgenic mouse models of human breast cancer
8. Mouse models of prostate cancer
9. Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes
10. b-restricted cytotoxic T lymphocyte epitopes within simian virus 40 T antigen
11. 8+ T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes
12. Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen
13. b-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen
14. b-restricted cytotoxic T lymphocyte epitopes in simian virus 40 tumor antigen
15. b-restricted determinant in simian virus 40 tumor antigen
16. b-restricted cytotoxic T-lymphocyte clones and a synthetic peptide
17. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope
18. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice
19. SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumors in transgenic mice
20. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice
21. Biology of simian virus 40 (SV40) transplantation rejection antigen (TrAg): In vitro demonstration of SV40 TrAg in SV40 infected non-permissive mouse cells by the lymphocyte-mediated cytotoxicity assay
22. Host resistance directed selectively against H-2-deficient lymphoma variants
23. Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-2130 in the absence of endogenous CD4 help, tumor necrosis factor α, γ interferon, perforin, or costimulation through CD28
24. Viral immune evasion due to persistence of activated T cells without effector function
25. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
26. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
27. T cell tolerance by clonal elimination in the thymus
28. + thymocytes
29. T lymphocyte tolerance: From thymic deletion to peripheral control mechanisms
30. Impact of negative selection on the T cell repertoire reactive to a self-peptide: A large fraction of T cell clones escapes clonal deletion
31. Tracing and characterization of the low-avidity self-specific T cell repertoire
32. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity
33. Cross-presentation: A general mechanism for CTL immunity and tolerance
34. Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity
35. Dendritic cells and the control of immunity
36. + T cells
37. Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens
38. + T cell tolerance to peripherally expressed antigens
39. Tumor antigens are constitutively presented in the draining lymph nodes
40. + T cell deletion induced by cross- presentation of self-antigens and favors autoimmunity
41. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas
42. Antibody response to human papovavirus JC (JCV) and simian virus 40 (SV40) T antigens in SV40 T antigen-transgenic mice
43. + T-helper and a T-killer cell
44. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
45. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
46. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes
47. Cross-presentation, dendritic cells, tolerance and immunity
48. Natural adjuvants: Endogenous activators of dendritic cells
49. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
50. The induction of tolerance by dendritic cells that have captured apoptotic cells
51. Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity
52. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway
53. + cells in vivo
54. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
55. Tolerance, danger, and the extended family
56. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
57. The functional significance of epitope spreading and its regulation by co-stimulatory molecules
58. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A
59. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
60. Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading
61. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
62. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
63. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
64. Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen
65. Coexpression of B7-1 and viral ("self") transgenes in pancreatic β cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes
66. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
67. The labyrinthine ways of cancer immunotherapy: T cell, tumor cell encounter: "How do I lose thee? Let me count the ways"
68. IL-12 treatment of endogenously arising murine brain tumors
69. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
70. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice
71. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model
72. Enhancement of antitumor immunity by CTLA-4 blockade